Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11747923 | 0.83 | MAPK1 (0.58) | MAPTRAB9ANPC1TSHRMAPK1 | |
| SCHEMBL13900098 | 0.83 | NPC1 (0.55) | MAPTRAB9ANPC1TSHRMAPK1 | |
| SCHEMBL28185992 | 0.81 | RAB9A (0.54) | MAPTRAB9ANPC1TSHRMAPK1 | |
| SCHEMBL27468736 | 0.81 | NPC1 (0.65) | MAPTRAB9ANPC1TSHRMAPK1 | |
| SCHEMBL14861314 | 0.81 | MAPT (0.60) | MAPTRAB9ANPC1MAPK1MEN1 | |
| SCHEMBL11502608 | 0.80 | KMT2A (0.63) | MAPTRAB9ANPC1TSHRMEN1 | |
| SCHEMBL306161 | 0.79 | POLB (0.81) | TSHRMAPK1MEN1KMT2APOLB | |
| SCHEMBL223451 | 0.79 | MAPT (0.63) | MAPTRAB9ANPC1TSHRMAPK1 | |
| SCHEMBL165760 | 0.79 | TSHR (0.62) | MAPTRAB9ANPC1TSHRMAPK1 | |
| SCHEMBL28454639 | 0.79 | MAPT (0.53) | MAPTRAB9ANPC1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036715-A | 2, 4-Diarylaminopyrimidine derivative containing benzodithioryl, and pharmaceutical composition and application thereof | 盐城工业职业技术学院 | 2026-05-15 | — | — | CN | disclosed |
| CN-118047779-B | Dihydropteridinone derivatives containing benzobisheteroaryl and use thereof | 沈阳药科大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-118047779-A | Dihydropteridinone derivatives containing benzobisheteroaryl and use thereof | 沈阳药科大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-113735756-B | Method for synthesizing chiral 3, 3-disubstituted isoindolinone compound by rhodium catalysis | 陕西师范大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-116574056-A | Preparation method of fluoroisoquinolone compound | 五邑大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-113735756-A | Method for synthesizing chiral 3, 3-disubstituted isoindolinone compound by rhodium catalysis | 陕西师范大学 | 2021-12-03 | — | — | CN | disclosed |
| CN-110305062-B | Substituted isoquinolone compound and synthesis method and application thereof | 广州医科大学 | 2021-01-05 | — | — | CN | disclosed |
| CN-107082761-B | Phenanthridinone or benzophenanthridinone derivative and synthesis method thereof | 上海大学 | 2020-04-03 | — | — | CN | disclosed |
| CN-110305062-A | Substituted isoquinoline ketone compounds and its synthetic method and application | 广州医科大学 | 2019-10-08 | — | — | CN | disclosed |
| CN-103288711-B | The preparation method of 3-hydroxyl-2-alkoxyl group-3-phenyl isoindole-1 (2H)-one analog derivative | TIANJIN UNIVERSITY (CN) | 2015-07-29 | — | — | CN | disclosed |
| CN-103288711-A | Preparation method of 3-hydroxy-2-alkoxy-3-phenyl-isoindol-1(2H)-ketone derivatives | UNIV TIANJIN | 2013-09-11 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MAPT 517/4885RAB9A 1648/4885NPC1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.